220 results
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
9 Apr 24
BrainStorm Cell Therapeutics Announces Agreement with FDA on a
6:05am
of neuroinflammation, neurodegeneration, and neuroprotection. An independent Data Monitoring Committee (DMC) will monitor the safety of the trial
8-K
BCLI
Brainstorm Cell Therapeutics, Inc.
20 Dec 23
BrainStorm Issues 2023 Letter to Shareholders
5:04pm
independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024 was approved, based upon the following votes
DEFA14A
kd1d d8ingxjk8oy7t
22 Nov 23
Additional proxy soliciting materials
4:00pm
8-K
EX-99.1
11ej3vnn
24 Oct 23
BrainStorm Cell Therapeutics Announces Strategic Realignment
7:30am
8-K
EX-10.1
tl30fyxphzs
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-10.2
qdh6ku
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-5.1
yybxiaff0lqfr2q
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
8-K
EX-4.1
dllqln7d3e blmcgia
19 Jul 23
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
4:05pm
424B5
et6awezyw
19 Jul 23
Prospectus supplement for primary offering
9:28am
8-K
EX-99.1
kjgqisv2bovpqt
20 Jun 23
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
5:01pm